Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The investigators will attempt to further increase the cure rate of ITP with medical therapy
by providing maintenance therapy with Mycophenolate mofetil (MMF) to persistent/chronic ITP
patients after treating them with induction therapy combining rituximab and dexamethasone.
The investigators will randomly assign patients to MMF versus placebo in order to demonstrate
safety (e.g., for infectious risk) and efficacy (platelet counts stably >50x109/L more than 1
year off therapy).